Summary
Stevanato Group Q2 Earnings Call Highlights
Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group S.p.A. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MPM Mark P. Mennitt CenterBook Partners LP | 87,299 | $1.76M | $1.84M | $81,188.07 | 4.62% |
 James D. King Lindenwold Advisors Inc. | 8,780 | $214,495.4 | $174,283 | -$40,212.4 | -18.75% |
 Adam J. Peck Riverwater Partners LLC | 247,454 | $4.47M | $5.21M | $739,887.21 | 16.55% |
 David Doumani PineStone Asset Management Inc. | 38,135 | $689,099 | $756,979.75 | $67,880.75 | 9.85% |
 Christopher C. Powers Farther Finance Advisors, LLC | 2,497 | $50,239.68 | $49,565.45 | -$674.23 | -1.34% |
Stevanato Group S.p.A. (STVN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Stevanato Group S.p.A. ever had a stock split?
Stevanato Group S.p.A. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Franco Stevanato CEO | NYSE Exchange | T9224W109 CUSIP |
| IT Country | 6,010 Employees | 11 Jun 2026 Last Dividend | - Last Split | 16 Jul 2021 IPO Date |
Overview
Stevanato Group S.p.A. is an influential entity specializing in the design, production, and distribution of a broad range of products and services tailored for the bio-pharma and healthcare industries. Established in 1949 and operating out of Piombino Dese, Italy, the company plays a pivotal role across various global markets including Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. Stevanato Group operates through two main business segments: Biopharmaceutical and Diagnostic Solutions; and Engineering. It stands as a key subsidiary of Stevanato Holding S.R.L., demonstrating a longstanding commitment to innovation and quality in the healthcare sector.
Products and Services
- Containment Solutions: These are designed to safely enclose pharmaceutical products, ensuring their integrity and protecting them from contamination.
- Drug Delivery Systems: Innovative systems that facilitate the administration of pharmaceuticals to patients, enhancing the effectiveness and user experience of medication therapies.
- Medical Devices: High-quality devices tailored for healthcare applications, contributing to diagnostics, treatment, and patient care.
- Diagnostic and Analytical Services: Services that support the healthcare industry by providing critical insights through diagnostics and advanced analytical technologies.
- Visual Inspection Machines: Sophisticated equipment designed for the inspection of pharmaceutical products, ensuring quality control and compliance with industry standards.
- Assembling and Packaging Machines: Machinery engineered for the efficient assembly and packaging of pharmaceuticals, ensuring product safety and streamlined manufacturing processes.
- Glass Forming Machines: Specialized equipment used in the manufacture of glass containers for pharmaceutical use, epitomizing precision and reliability.
